HAYWARD,
Calif., April 21, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced an upcoming podium
presentation on DSUVIA (sufentanil sublingual tablet, 30 mcg) which
will be presented at the annual meeting of The Aesthetic Society®,
"The Aesthetic Meeting 2022", held from April 20 -24 at the San
Diego Convention Center.
Hisham Seify, MD, PhD, FACS will
present efficacy and safety data on the use of DSUVIA for both
"awake" cosmetic procedures as well as for general anesthesia
plastic surgery procedures. All data derive from patient
cases at the Newport Plastic and Reconstructive Surgery's center
and AcelRx provided support for one of the trials from which data
will be presented. Dr. Seify is a board-certified plastic
surgeon and the past-president of the Orange County Society of
Plastic Surgeons. In addition to being in private practice in
Newport Beach CA, Dr. Seify is
also Associate Clinical Professor at the David Geffen UCLA School
of Medicine.
Session Title: Scientific Paper Session
Presentation Title: Improved Patient Experience and Opioid
Minimalization in Outpatient Plastic Surgery Procedures Using a
Sufentanil Sublingual Tablet
Session Date: Sunday, April 24,
2022
Session Time: 9:15 am –
9:22 am Pacific Daylight Time
About DSUVIA (sufentanil sublingual tablet, 30
mcg)
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in
certified medically supervised healthcare settings, such as
hospitals, surgical centers, and emergency departments, for the
management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile, when
delivered sublingually, avoids the high peak plasma levels and
short duration of action observed with IV administration. DZUVEO
has been approved by the European Medicines Agency and AcelRx's
European commercialization partner, Aguettant, will market the drug
in Europe.
This release is intended for investors only. For more
information, including important safety information and a black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA® (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO® in
Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and several product candidates, including the
following: Zalviso® (sufentanil sublingual tablet
system, SST system, 15 mcg), an investigational product in the U.S.
being developed as an innovatively designed patient-controlled
analgesia (PCA) system for reduction of moderate-to-severe acute
pain in medically supervised settings; two pre-filled, ready-to-use
syringes of ephedrine and phenylephrine licensed for the U.S. from
Aguettant; Niyad™ (nafamostat mesylate), a regional anticoagulant
for the extracorporeal circuit; and, LTX-608 for the potential
treatment of COVID-19, disseminated intravascular coagulation,
acute respiratory distress syndrome and acute pancreatitis. DZUVEO
and Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
This release is intended for investors only.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-upcoming-podium-presentation-on-use-of-dsuvia-for-plastic-surgery-procedures-at-the-aesthetic-meeting-2022-301530024.html
SOURCE AcelRx Pharmaceuticals, Inc.